Bivalirudin More Beneficial than Heparin in Patients with AMI Undergoing PCI: The BRIGHT Trial

Article Figures & Data

Figures

  • Figure 1.

    NACE, MACCE, and Any Bleeding at 30 Days

    Biv, bivalirudin; H + T, heparin plus tirofiban; MACCE, major adverse cardiac and cerebrovascular events; NACE, adverse clinical events; UFH, unfractionated heparin.Reproduced with permission from Y Han, MD.
  • Figure 2.

    NACE at 1 Year

    Biv, bivalirudin; H + T, heparin plus tirofiban; NACE, adverse clinical events; UFH, unfractionated heparin.Reproduced with permission from Y Han, MD.
  • Figure 3.

    Treatment-Related Bleeding

    Biv, bivalirudin; H + T, heparin plus tirofiban; UFH, unfractionated heparin.Reproduced with permission from Y Han, MD.